Hemopoietic stem-cell harvesting and transplantation using G-CSF-primed BM: comparison with unprimed BM and G-CSF-primed PBSC

Lowenthal, RM; Tuck, DM; Tegg, Elizabeth; Marsden, Kate; Rees, B; Luck, J; Ragg, SJ; Parker, N; Kotlovsky, NN

doi:10.1080/0032472031000141285

Cited by 4 publications

(1 citation statement)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Moreover, our results appear to be superior when compared to patients who received a non-G-CSF-primed standard volume bone marrow transplant or an ex vivo expanded small volume bone marrow transplant, regardless of G-CSF priming (AastromReplicell system) with reported recoveries of 500 neutrophils/l and 20 000 platelets/l at medians of 14 and 16 and 22 and 24 days, respectively. 16,24 Despite extensive washing, infusion of the expanded product may result in allergic-type reactions, thus patients need to be observed carefully in a controlled, setting, particularly those with a history of allergy.…”

Section: Cd34mentioning

confidence: 99%

A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation

Pecora

Stiff

LeMaistre³

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:To reduce the number of apheresis procedures and maintain the usual rate of hematopoietic recovery in patients treated with high-dose chemotherapy, we studied the effect of adding a small volume of ex vivo expanded bone marrow to low doses of CD34 + blood stem cells. Thirty-four patients with breast cancer received G-CSF (10 g/kg/day) priming followed by a limited volume (50-100 ml) bone marrow aspiration and standard 10-liter aphereses. Marrow was expanded ex vivo using the AastromReplicell system and infused along with low doses of blood-derived CD34 + cells, collected in one apheresis. Thirty-one evaluable patients received a median CD34 + blood stem cell dose of 0.7 × 10 6 /kg (range, 0.2-2.5) and 4.7 × 10 7 nucleated cells/kg (range, 1.98-8.7) of ex vivo expanded marrow. All patients recovered with normal blood counts and engrafted 500 neutrophils/l and 20 000 platelets/l in a median of 10 and 13 days, respectively. Multivariate analysis revealed that, in addition to CD34 + lineage negative cell quantity, the quantity of stromal progenitors contained in the ex vivo expanded product correlated with engraftment outcome (r = 0.551, P = 0.004

show abstract

Section: Cd34mentioning

confidence: 99%

A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation

Pecora

Stiff

LeMaistre³

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

Untitled

Lowenthal

Graham

2000

Journal of Clinical Immunology

View full text Add to dashboard Cite

Based on animal models and limited clinical experience, there is considerable interest in use of high-dose immunosuppression followed by hemopoietic stem cell transplantation as treatment for severe rheumatoid arthritis. Because of its relatively low treatment-related mortality and morbidity, autologous transplantation is a more attractive option than allogeneic transplantation for initial clinical trials, even though anecdotal reports suggest that allogeneic transplantation has a greater likelihood of bringing about long-term disease control. The approach remains experimental with many unanswered questions such as the value and safety of high-dose therapy without transplantation, the need for T cell purging, the possible deleterious effects of post-transplant hemopoietic growth factors and the potential of "mini" allogeneic transplantation (a process whereby intense immunosuppression is combined with less intense myelosuppression). To achieve quick progress it is essential that clinical trials be carefully designed with all cases being reported to the Autoimmune Disease Stem Cell Project Database.

show abstract

Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation

Tegg

Griffiths

Lowenthal

et al. 2001

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:We studied interleukin-6 (IL-6) levels on the day of transplantation in 31 patients undergoing autologous haemopoietic stem cell transplantation (SCT) (either peripheral blood stem cell transplantation (PBSCT) or bone marrow transplantation (BMT)) for neoplastic diseases to determine if there was a relationship between IL-6 level and rate of haemopoietic recovery, length of stay in hospital, and survival. There was no apparent delay in post-transplant recovery associated with elevated IL-6 levels. However, increased values of IL-6 tended to be associated with an increased length of stay in hospital (P = 0.083). There was a highly significant adverse association between higher IL-6 levels and survival following transplantation (P = 0.0001). This association remained significant (P = 0.013) in the uniform subgroup of patients with malignant lymphoma with chemosensitive disease who had undergone BMT (that is, excluding patients who had undergone PBSCT) (n = 13). Knowledge of IL-6 levels on the day of transplant has the potential to provide valuable prognostic information in patients undergoing autologous haemopoietic SCT. Bone Marrow Transplantation (2001) 28, 929-933.

show abstract

Hemopoietic stem-cell harvesting and transplantation using G-CSF-primed BM: comparison with unprimed BM and G-CSF-primed PBSC

Cited by 4 publications

References 31 publications

A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation

A phase II trial evaluating the safety and effectiveness of the AastromReplicell system for augmentation of low-dose blood stem cell transplantation

Untitled

Association between high interleukin-6 levels and adverse outcome after autologous haemopoietic stem cell transplantation

Contact Info

Product

Resources

About